drugset / Trial / NCT05192174
Study of NIB101 in Participants With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
NIB101-01 study is an open-label, non-randomized Phase 1 study in participants with GM2 positive advanced solid tumor, who failed to available standard of cares to evaluate the safety and tolerability of NIB101.
Timeline
- Start
- 2022-01-24
- Primary completion
- 2025-05-16
- Completion
- 2025-05-16
Outcome
Outcome not reported
Stopped (Business): “due to the reconsideration of development strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIB101 | Unknown | 1e+07 cells | Intravenous |
| Subject | NIB101 | Unknown | 1e+08 cells | Intravenous |